Reviewer's report

Title: Patan Hospital Experience In Treating Philadelphia Chromosome/BCR-ABL1 Positive Chronic Myeloid Leukemia Patients With Gleevec (Imatinib Mesylate); The First Generation Specific Tyrosine Kinase Inhibitor.

Version: 1 Date: 16 March 2010

Reviewer: michael J mauro

Reviewer's report:

1. Is the question posed by the authors well defined? YES
2. Are the methods appropriate and well described? YES
3. Are the data sound? YES
4. Does the manuscript adhere to the relevant standards for reporting and data deposition? YES
5. Are the discussion and conclusions well balanced and adequately supported by the data? YES
6. Are limitations of the work clearly stated? YES
7. Do the authors clearly acknowledge any work upon which they are building, both published and unpublished YES
8. Do the title and abstract accurately convey what has been found? YES
9. Is the writing acceptable? YES

- Major Compulsory Revisions
  Further clarification on cytogenetic response timing is needed to help understand and round out the discussion of the good response, close follow-up yet lack of response data in this cohort / experience

- Minor Essential Revisions
  Please state location of centre in background of abstract
  Please clarify “a few patients developed non-hematologic toxicity” in results of abstract
  Please state at what point cytogenetic analyses were done for patients as this aids in understanding the logistics of the regional practice in addition to the adherence to relevant timepoints after diagnosis and outcomes (see above)

Level of interest: An article whose findings are important to those with closely related research interests
Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.